Payment & Shipping Terms:
|Type:||Pharmaceutical Intermediate||Appearance:||White Powder|
Pharma Raw Materials,
|Product Categories:||Intracellular receptor;Steroid and Hormone;Active Pharmaceutical Ingredients;API;Biochemistry;PROSCAR;-;Steroids;Steroids (Others);Intermediates & Fine Chemicals;Pharmaceuticals;Vitamin Ingredients;Hormone Drugs|
One brand of this drug (Proscar) is used to treat the symptoms of enlarged prostate (benign prostate hyperplasia). It may be used as part of a combination therapy. That means you need to take it with other drugs. It also can be taken with doxazosin to reduce the risk of progression of symptoms of enlarged prostate (benign prostatic hyperplasia).
This medication in a long - term efficacy and safety of ( PLESS ), in the study of symptoms of moderate to severe hyperplasia of prostate, 3016 prostate hyperplasia patients treated with this drug is 4 years relevant disposal ( surgical intervention ), urinary system such as transurethral resection of the prostate gland and other resection of the prostate, or need to insert the catheter acute urinary retention is evaluated.In this double - blind, randomized, placebo - controlled, multicenter study, treatment with this drug to the disposal of the overall risk of urinary system was reduced by 51%, with significant and sustained of prostate volume shrinking, and continuous maximum urinary flow rate increased and the symptoms improve.
(1) Benign prostatic hyperplasia:
Physicians use finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.
(2) Male pattern baldness:
Three Phase 3 clinical trials examined the efficacy of finasteride in the treatment of mild to moderate male pattern baldness. The primary endpoints of each trial were hair count and user self-assessment. Secondary endpoints included investigator assessment and examination of scalp photographs. Each patient also filled out questionairres regarding sexual health and non-scalp body hair growth. These trials enrolled 1879 men and had a duration of one year. Of these 1879 men, 1215 elected to participate in a one year double blind extension trial. Additional extension trials were performed such that 323 men experienced over 4 years of treatment.
we, Yihan Industrial Co., Ltd from china are specilized in steroids powder , semi-finished liquids , peptides , Sarm powder,HGH,HCG,Finished Liquid and other pharmaceutical materials for many years .
If you have any further questions or need a sample,Please do not hesitate to contact me.Thank you!